Oncternal Therapeutics (NASDAQ:ONCT) Price Target Cut to $18.00 by Analysts at HC Wainwright

Oncternal Therapeutics (NASDAQ:ONCT) had its target price cut by HC Wainwright from $19.00 to $18.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, StockNews.com assumed coverage on Oncternal Therapeutics in a research note on Wednesday, August 7th. They issued a hold rating for the company.

Oncternal Therapeutics Trading Down 6.2 %

Shares of NASDAQ ONCT opened at $3.80 on Monday. The company has a market cap of $11.25 million, a price-to-earnings ratio of -0.31 and a beta of 1.36. Oncternal Therapeutics has a 12 month low of $3.80 and a 12 month high of $13.14. The stock has a 50-day moving average price of $6.98 and a two-hundred day moving average price of $8.25.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the prior year, the firm posted ($3.00) earnings per share. On average, sell-side analysts predict that Oncternal Therapeutics will post -11.63 earnings per share for the current year.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.